FDA Joining NIH To Discuss Therapeutic Potential Of Cannabinoids

FDA will join representatives from the National Institutes of Health (NIH), the Drug Enforcement Administration, academia and industry to discuss the regulatory landscape and future research opportunities of cannabinoids during a Dec. 8 workshop, NIH announced on the Federal Register Monday (Dec. 3). The goal of the meeting, according to NIH’s agenda, is to: gain an understanding of how to navigate the regulatory space; inform the research and regulatory community of the National Center for Complementary and Integrative Health...